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Abstract
We conducted a systematic review of the 2012-2013 multistate fungal meningitis epidemic in the 
United States from the perspectives of clinical response, outbreak investigation, and 
epidemiology. Articles focused on clinical response, outbreak investigation, and epidemiology 
were included, whereas articles focused on compounding pharmacies, legislation and litigation, 
diagnostics, microbiology, and pathogenesis were excluded. We reviewed 19 articles by use of the 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework. The 
source of the fungal meningitis outbreak was traced to the New England Compounding Center in 
Massachusetts, where injectable methylprednisolone acetate products were contaminated with the 
predominant pathogen, Exserohilum rostratum. As of October 23, 2013, the final case count stood 
at 751 patients and 64 deaths, and no additional cases are anticipated. The multisectoral public 
health response to the fungal meningitis epidemic from the hospitals, clinics, pharmacies, and the 
public health system at the local, state, and federal levels led to an efficient epidemiological 
investigation to trace the outbreak source and rapid implementation of multiple response plans. 
This systematic review reaffirms the effective execution of a multisectoral public health response 
and efficient delivery of the core functions of public health assessment, policy development, and 
service assurances to improve population health.
Correspondence and reprint requests to Kaja M. Abbas, Department of Population Health Sciences, Virginia Tech, Blacksburg, VA 
24061 (kaja.abbas@vt.edu). 
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On September 18, 2012, a clinician reported to the Tennessee Department of Health a 
patient diagnosed with culture-confirmed Aspergillus fumigatus meningitis, 46 days after an 
epidural steroid injection.1,2 This patient was the index case of the 2012-2013 multistate 
fungal meningitis epidemic in the United States.
The source of the fungal meningitis epidemic was traced to contaminated lots of 
preservative-free methylprednisolone acetate that had been used for epidural steroid 
injections and had been produced at the New England Compounding Center in 
Massachusetts.3 The New England Compounding Center recalled injectable 
methylprednisolone acetate products, which eventually expanded to all drug products, and 
completely ceased drug production.
The timeline of the fungal meningitis outbreak response is illustrated in Figure 1. 
Contaminated lots of preservative-free methylprednisolone acetate were used in epidural 
steroid injections from July 30, 2012, to September 18, 2012, until the first case of fungal 
meningitis was confirmed in Tennessee on September 18, 2012. A total of 23 states had 
received contaminated lots of preservative-free methylprednisolone acetate from July 30, 
2012, to September 18, 2012. The Centers for Disease Control and Prevention (CDC) 
released interim treatment guidelines for fungal meningitis on October 19, 2012, which 
recommended voriconazole therapy, which was prescribed for all patients in Virginia and 
other affected states. Michigan performed follow-up magnetic resonance imaging (MRI) on 
patients for 6 months until April 2013. The final case count stood at 751 patients and 64 
deaths, and 20 affected states, as of October 23, 2013, and no additional cases are 
anticipated.
The fungal meningitis epidemic was controlled through a multisectoral response from the 
affected patients, immediate caregivers of family and friends, hospitals and pharmacies, and 
public health departments at the local, state, and federal levels, as illustrated in Figure 2. 
Clinics and local health departments contacted the patients who had received the 
contaminated epidural steroid injections and referred probable cases for clinical services and 
hospitalization. Patients exposed to fungal-contaminated epidural injections were followed 
up for 6 months and were provided appropriate treatment including lab tests and 
hospitalizations.
The objective of the present study was to conduct a systematic review of the multistate 
fungal meningitis outbreak response in the United States, with a focus on clinical response, 
outbreak investigation, and epidemiology. We focused this systematic review on the 
coordinated response and partnership between the clinical system and the public health 
departments at the local, state, and federal levels to understand the public health assessment, 
policy development, and service assurances in control and prevention of the fungal 
meningitis epidemic. Systematic understanding of the multisectoral outbreak response to the 
fungal meningitis epidemic will assist in analyzing this response and improve the emergency 
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preparedness of the health departments to prevent and control future outbreaks effectively 
and efficiently. The public health significance of this systematic review of the fungal 
meningitis epidemic is to analyze the implementation of the public health core 
responsibilities of assessment, policy development, assurance, and related essential services 
in protecting the health of the public.
Systematic Review
Search Strategy
We searched the PubMed database for articles published from September 1, 2012, to April 
30, 2015, with the terms (“meningitis, fungal” or [“meningitis” and “fungal”] or “fungal 
meningitis” or [“fungal” and “meningitis”]) and (“disease outbreaks” or [“disease” and 
“outbreaks”] or “disease outbreaks” or “outbreak”).
Data Abstraction and Synthesis
The data abstraction and synthesis process was conducted by 2 authors (KMA and ND) 
independently. We resolved discordant decisions through consensus. Data abstraction and 
synthesis included the following 4 steps: identification, screening, eligibility, and inclusion. 
During the identification step, articles were identified by using the search strategy 
mentioned above. During the screening step, duplicate articles were removed, and titles and 
abstracts of the remaining articles were screened to determine their relevance to our study 
objectives. During the eligibility step, the full text of the articles was analyzed to determine 
their relevance to our study objectives.
Inclusion and Exclusion Criteria
The inclusion criteria were articles focused on clinical response, outbreak investigation, and 
epidemiology. Exclusion criteria were articles focused on compounding pharmacies, 
legislation and litigation, diagnostics, microbiology, pathogenesis, press releases, editorials, 
and other diseases or outbreaks.
PRISMA Process
Figure 3 illustrates the process flow diagram of identification, screening, eligibility, and 
inclusion of articles for the systematic review by use of the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) flow diagram.4 Nineteen articles met the 
selection criteria for the systematic review of the fungal meningitis epidemic. Articles were 
categorized by clinical response, outbreak investigation, and epidemiology.
Clinical Response
The clinical response to the fungal meningitis epidemic is summarized in Table 1.
Interim Treatment Guidelines
The CDC released interim guidelines for fungal meningitis treatment in the Morbidity and 
Mortality Weekly Report on October 19, 2012. Voriconazole was recommended as effective 
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in treating infections caused by the predominant pathogen, Exserohilum rostratum, in this 
outbreak.3
Evolving Treatment Guidelines
The fungal meningitis patients presented with a broad spectrum of clinical disease, reflecting 
the differences in pathogenesis, exposure, and host risk factors. Treatment guidelines issued 
by the CDC initially recommended high-dose dual therapy with voriconazole and liposomal 
amphotericin B, which was revised to monotherapy with voriconazole for patients without 
serious illness. Treatment recommendations were updated as the fungal meningitis outbreak 
evolved as new clinical evidence emerged during therapeutic management of affected 
patients.5 More than 90% of patients at risk of developing fungal infection following the 
contaminated epidural injections were asymptomatic and did not develop any infection. 
Pharmacies involved in the outbreak response were challenged by both clinical and 
administrative issues while adapting to the evolving treatment guidelines from the CDC.6
Voriconazole Therapy
On the basis of a case series analysis of 172 patients who had epidural steroid injections and 
presented for care at a hospital in Virginia from October 4, 2012, to October 31, 2012, 
voriconazole therapy was prescribed for all patients.7 Meningitis was diagnosed in most of 
these patients, and the voriconazole therapy improved prognosis within the treated patient 
cohort.
Michigan Hospital
In November 2012, St. Joseph Mercy Ann Arbor hospital cared for 123 patients or 85% of 
the cases in Michigan, which related to 25% of the total cases nationally during this time.8 A 
total of 620 patients had received contaminated steroid injections from the same pain clinic 
located 26 miles from the hospital. The high proportion of infections from this clinic was 
due to “hot lots” of steroids received at this clinic; these drug lots were associated with a 
large number of infections. The Saint Joseph Mercy hospital identified a cluster of fungal 
meningitis cases immediately after the onset of the outbreak in Tennessee. The treatment 
familiarity led to a centralized approach of consistent care delivery and care management at 
Saint Joseph Mercy hospital, which became the default health facility for the infected 
patients in Michigan to seek treatment. Owing to the long-term uncertainty about the natural 
progression of fungal meningitis, it was recommended that patients continue oral 
voriconazole treatment at home following hospital release for months based on the follow-
up tests and disease progression.9 The patients were closely monitored for optimal drug 
intake and any adverse side effects. MRI was performed on 172 patients between November 
9, 2012, and April 30, 2013; these patients had received “hot lot” steroids but had not 
presented for clinical care for treatment of adverse effects.10 Of these patients, 21% had 
abnormal MRI findings and were initiated on early medical or surgical treatment for spinal 
infections. As of January 31, 2014, a total of 153 patients had been diagnosed at Saint 
Joseph Mercy hospital for probable or confirmed spinal or paraspinal infection at the 
injection site, of which 78 patients were confirmed to have fungal infection. Voriconazole 
was prescribed as the drug therapy for all 153 patients, among which 115 patients were also 
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prescribed liposomal amphotericin B.11 A total of 20 patients remained on an azole agent as 
of January 31, 2014.
Risk of Fungal Infection
Pappas reviewed the risk of developing fungal infection following an injection of 
contaminated methylprednisolone acetate.12 Less than 10% of patients at risk developed any 
symptoms of infection, and among symptomatic patients, some developed meningitis while 
others developed epidural abscess and other parameningeal complications. There was no 
consensus in the management of exposed asymptomatic patients and symptomatic patients 
with negative lab test results, such as cerebrospinal fluid, glucose, protein, and imaging 
tests. Thereby, there were variations in the clinical treatment of exposed patients who were 
symptomatic or asymptomatic.
Outbreak Investigation
The outbreak investigation of the fungal meningitis epidemic is summarized in Table 2.
Public Health Preparedness
Bell and Khabbaz illustrate the value of public health preparedness in detection and response 
to emerging infections.13 During the fungal meningitis outbreak, collaboration between the 
public health system with essential health care partners in the private sector, industry, and 
academia enabled effective control and prevention interventions. The outbreak response 
included detection of an infection cluster to the rare pathogen, followed by rapid 
implementation of multiple response plans, which led to a decrease in the case fatality rate 
among the fungal meningitis patients.
Multisectoral Response
The public health system of CDC (in collaboration with the Food and Drug Administration), 
state and local health departments, along with the clinical system of clinics, hospitals, and 
pharmacies collaborated well in prevention and control of the fungal meningitis outbreak.14 
While the clinical system identified and treated the patients to control the rare invasive 
fungal infection, the public health system conducted a rapid epidemiological investigation to 
trace the source of the outbreak to the New England Compounding Center to prevent 
additional fungal infections. The New England Compounding Center responded by recalling 
all injectable methylprednisolone acetate products, which eventually expanded to all drug 
products and a complete ceasing of drug production.
Hybrid Surveillance Strategy
The Virginia Department of Health implemented a hybrid active public health surveillance 
system for control and prevention of the fungal meningitis outbreak in Virginia, in 
partnership with clinical stakeholders.15 Division of labor was coordinated to improve 
efficiency of the outbreak response, with clinicians focused on diagnosis and treatment, 
while the health departments undertook weekly surveillance phone calls to exposed patients 
who were not in clinical care.
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Epidemiology
The epidemiology of the fungal meningitis epidemic is summarized in Table 3.
Six states: Florida, Indiana, Michigan, New Jersey, Tennessee, and Virginia
Chiller et al reviewed the case records of 328 patients from the 6 states (Florida, Indiana, 
Michigan, New Jersey, Tennessee, Virginia) with the most reported cases through 
November 19, 2012.16 On the basis of their initial clinical findings, they concluded that the 
fungal infections during this outbreak caused a broad spectrum of clinical disease, reflecting 
the differences in pathogenesis, exposure route, and host risk factors.
Clinic: Tennessee
Kainer et al conducted a cohort analysis at both the patient and procedure levels on all 
patients who had been given epidural or paraspinal glucocorticoid injections at a single 
clinic in Tennessee since July 1, 2012, to evaluate risk factors for infection.2 Cases were 
defined as patients who developed fungal meningitis, posterior circulation stroke, spinal 
osteomyelitis, or epidural abscess after injection. The median age of the cases was 69 years 
(range, 23-91 years). The median time from the last injection to symptom onset was 18 days 
(range, 0-56 days), with meningitis alone among 73% of patients. A total of 22 patients were 
confirmed by lab tests to have Exserohilum rostratum (21 patients) and Aspergillus 
fumigatus (1 patient) infections; 8 patients died, of which 7 deaths were due to stroke. The 
infection risk was high among patients exposed to lot number 06292012@26, older vials, 
higher doses, and multiple procedures and in patients in whom a translaminar approach was 
used for the epidural glucocorticoid injection.
Morbidity and Mortality Rates
Morbidity and mortality rates were estimated for the multistate fungal meningitis outbreak 
by analyzing clinical data contained in the standardized case reports.17 After contacting 
more than 99% of 13,534 potential exposed patients by July 1, 2013, there were 749 
reported cases with 61 deaths (8%); 40 patients (5%) had a stroke, and 229 (31%) patients 
(of 728 case patients with additional data) had meningitis. Specimens from patients were 
tested for presence of fungi, and laboratory evidence confirmed the presence of Exserohilum 
rostratum in specimens of 153 case patients (20%). One injection (range, 1-6) from the 
implicated methylprednisolone acetate lots was administered among the case patients, with a 
median age of 64 years (range, 15-97 years) and median incubation period of 48 days 
(range, 0-249 days) from the last injection to diagnosis.
Morbidity and Mortality Reports: CDC
The CDC released morbidity and mortality reports at the onset and throughout the multistate 
fungal meningitis outbreak affecting the 20 states.1,18,19 The CDC also maintained a website 
with real-time information on the outbreak investigation and additional information for 
patients, clinicians, and laboratories.20 As of October 23, 2013, the case count stood at 751 
patients with 64 deaths, with no additional cases anticipated. A total of 233 patients had 
meningitis only, 325 patients had paraspinal/spinal infection only, 33 patients had peripheral 
joint infection only, 151 patients had both meningitis and paraspinal/spinal infection, 2 
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patients had paraspinal/spinal infection and peripheral joint infection, and 7 patients had 
strokes.
Discussion
Multisectoral Collaboration
Multisectoral collaboration between the public health system at the local, state, and federal 
levels and the clinical system led to effective control of the fungal meningitis outbreak. The 
collaboration facilitated efficient epidemiological investigation, right from the detection of 
the index case and the infection cluster of the rare pathogen to rapid tracing of the outbreak 
source and followed by effective implementation of multiple response plans.
Essential Services in Public Health
The fungal meningitis outbreak response reflects both public health best practices and 
fidelity to the core responsibilities and essential services in public health, as promoted by the 
Institute of Medicine (IOM) and institutionalized in public health.21,22 The IOM reports on 
the future of public health conceptualized the core functions of public health assessment, 
policy development, and service assurances. The reports presented a multisectoral public 
health system framework of government public health agencies, working with multiple 
partners from the public and private sectors to improve population health. In the fungal 
meningitis outbreak response, public health assessment was accomplished through near real-
time analysis of clinical and epidemiological data to trace the source of the outbreak. Policy 
development included written directives and procedures, with close attention to legalities 
and regulations, to prevent and control the spread of the fungal meningitis outbreak. Service 
assurances in the fungal meningitis outbreak response were accomplished through support of 
compliance efforts and enforcement throughout the multisectoral public health system.
Public Health Implications
We conducted a systematic review of the multisectoral outbreak response to the 2012-2013 
multistate fungal meningitis epidemic in the United States from the perspectives of clinical 
response, outbreak investigation, and epidemiology. This systematic analysis of the well-
coordinated outbreak response will assist in the preparedness of public health and clinical 
systems in the control and prevention of future outbreaks.
Limitations
The limitations of this systematic review were the exclusion of communication, such as 
phone calls and e-mails, between health departments at local, state, and federal levels and 
other stakeholders, such as clinicians, pharmacies, and insurance agencies, and regular 
follow-up communication by clinicians and local health departments with affected patients 
during the course of the fungal meningitis outbreak.
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Figure 1. 
Timeline of the Fungal Meningitis Outbreak. The first case was confirmed in Tennessee on 
September 18, 2012. Twenty-three states had received contaminated lots of preservative-free 
methylprednisolone acetate, and 20 states reported confirmed cases of fungal meningitis. As 
of October 23, 2013, the case count stood at 751 patients and 64 deaths, and no additional 
cases are anticipated. Abbreviation: MMWR, Morbidity and Mortality Weekly Report.
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Figure 2. 
Multisectoral Public Health Response. The fungal meningitis epidemic was controlled 
through a multisectoral response from the affected patients, immediate caregivers of family 
and friends, hospitals and pharmacies, and public health departments at the local, state, and 
federal levels. Abbreviations: CDC, Centers for Disease Control and Prevention; FDA, Food 
and Drug Administration.
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Figure 3. 
PRISMA Flowchart. The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram of articles' identification, screening, eligibility, and 
inclusion in the systematic review is illustrated. Articles focused on clinical response, 
outbreak investigation, and epidemiology were included, whereas articles focused on 
compounding pharmacies, legislation and litigation, diagnostics, microbiology, 
pathogenesis, press releases, editorials, and other diseases or outbreaks were excluded.
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Table 1
Clinical Response to the Fungal Meningitis Epidemica
Reference Inferences
3 CDC recommends voriconazole as an effective drug to treat infections caused by the predominant pathogen, Exserohilum 
rostratum.
5,6 Pharmacies adapted to the emerging clinical evidence and evolving treatment recommendations from the CDC; high-dose dual 
therapy with voriconazole and liposomal amphotericin B was revised to monotherapy with voriconazole for patients without 
serious illness.
7 172 patients were exposed to contaminated epidural steroid injections and presented for care in a Virginia hospital; most of these 
patients were diagnosed with meningitis and most patients improved their health with voriconazole therapy.
8 Fungal meningitis treatment familiarity at Saint Joseph Mercy hospital led to a centralized approach of consistent care delivery 
and care management for the infected patients in Michigan.
9 The novelty of the fungal meningitis infections led to long-term uncertainty about their clinical progression, and patients were 
closely monitored for optimal drug intake and any adverse effects.
10 Patients were recommended to continue oral voriconazole treatment at home, following hospital release for months based on the 
follow-up tests and disease progression.
10 Magnetic resonance imaging screenings assisted in identifying patients for initiating early medical or surgical treatment.
11 Voriconazole drug therapy was prescribed for all 153 patients with probable or confirmed spinal or paraspinal infection at the 
Saint Joseph Mercy hospital in Michigan, with liposomal amphotericin B also prescribed for 75% of these patients.
12 There is no consensus in management of exposed asymptomatic patients and symptomatic patients with negative lab tests, 
thereby leading to variations in clinical treatment of exposed patients, both symptomatic and asymptomatic.
aAbbreviation: CDC, Centers for Disease Control and Prevention.
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Table 2
Outbreak Investigation of the Fungal Meningitis Epidemic
Reference Inferences
13 Collaboration between the public health system and essential health care partners led to an effective outbreak response, including 
the detection of infection cluster to the rare pathogen, followed by rapid implementation of multiple response plans.
14 Good collaboration between the public health and clinical systems in controlling the fungal meningitis outbreak facilitated the 
fast-moving epidemiological investigation to rapidly trace the outbreak to its source.
15 A hybrid active public health surveillance system was implemented by the Virginia Department of Health, in partnership with 
clinical stakeholders, for control and prevention of the fungal meningitis outbreak in Virginia.
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Table 3
Epidemiology of the Fungal Meningitis Epidemic
Reference Inferences
16 The fungal meningitis cases presented a broad spectrum of clinical disease, reflecting the differences in pathogenesis, exposure, 
and host risk factors.
2 Cohort analysis on patients who had been given epidural or paraspinal glucocorticoid injections in Tennessee showed that the 
infection risk was high among patients exposed to lot 06292012@26, older vials, higher doses, multiple procedures and in 
patients in whom a translaminar approach to epidural glucocorticoid injection was used.
17 As of July 1, 2013, morbidity and mortality rates of the multistate fungal meningitis outbreak were estimated at 749 reported 
cases with 61 deaths (8%); 40 patients (5%) had stroke, and 229 (31%) patients had meningitis.
1,18–20 As of October 23, 2013, the multistate fungal meningitis outbreak had affected 20 states and the case count stood at 751 patients 
with 64 deaths, with no additional cases anticipated. A total of 233 patients had meningitis only, 325 patients had paraspinal/
spinal infection only, 33 patients had peripheral joint infection only, 151 patients had meningitis and paraspinal/spinal infection, 2 
patients had paraspinal/spinal infection and peripheral joint infection, and 7 patients had stroke.
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